UX-DA003 stem cell injection for people with Parkinson's disease
Tests UX-DA003, made from stem cells, in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease
Key facts
- Where
- Hefei, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 75 years old?
Source: NCT07911670, who can take part
Where in China
- The First Affiliated Hospital of Anhui Medical University RecruitingHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Anhui Medical University
- Trial code
- NCT07911670
- Record updated
- 3 November 2026
- Original description
This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.Read full original descriptionShow less
Exploratory Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of UX-DA003 Injection (Human iPSC-derived Midbrain Dopaminergic Neural Precursor Cells) in Patients With Parkinson's Disease
This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
Inclusion: - Aged between 30 and 75 years, regardless of gender; Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years; Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined; Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%; The modified H\&Y staging (Off period) of ≥2.5 and ≤4, with total daily "off" time >2 hours; Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening; Good physical condition or stable concomitant diseases.
Exclusion: Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders; Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT/MRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks; Subjects with a history of severe allergies or hypersensitivity reactions, known hypersensitivity to the investigational drug or its ancillary materials, or intolerance to them; The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome; Severe systemic diseases or functional impairments; Evidence of active infection or chronic infection, which may pose a risk to the subject; Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months; Pregnant or breastfeeding women.